MX366967B - Combinaciones de farmacos. - Google Patents
Combinaciones de farmacos.Info
- Publication number
- MX366967B MX366967B MX2015011147A MX2015011147A MX366967B MX 366967 B MX366967 B MX 366967B MX 2015011147 A MX2015011147 A MX 2015011147A MX 2015011147 A MX2015011147 A MX 2015011147A MX 366967 B MX366967 B MX 366967B
- Authority
- MX
- Mexico
- Prior art keywords
- decitabine
- derivatives
- combinations
- drug combinations
- cancers
- Prior art date
Links
- 239000000890 drug combination Substances 0.000 title 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical class O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 abstract 2
- 208000023661 Haematological disease Diseases 0.000 abstract 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- -1 cancer vaccines Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001766 physiological effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a una combinación que comprende los siguientes componentes separados: (i) un compuesto de fórmula I o una sal farmacéuticamente aceptable de este: (grupo 5-azacitosina)-L-(grupo guanina) (I) en donde L es un enlazador que contiene fósforo de fórmula (II): en donde R1 y R2 son independientes H, OH, un grupo alcoxi, un grupo alcoxialcoxi, un grupo aciloxi, un grupo carbonato, un grupo carbamato o un halógeno; R3 es H, o R3, junto con el átomo de oxígeno al cual R3 está unido, forma un éter, un éster, un carbonato o un carbamato; R4 es H o R4, junto con el átomo de oxígeno al cual R4 está unido, forma un éter, un éster, un carbonato o un carbamato; y X, junto con los átomos de ox´geno a los cuales X está unido forma un fosfodiéster, un diéster de fosforotioato, un diéster de boranofosfato o un diéster de metilfosfonato; y (ii) uno o más componentes terapeúticos complementarios en donde dicho componente terapéutico complementario es un agente de activación de linfocitos T; en donde dicho compuesto de fórmula I o una sal farmacéuticamente aceptable está adaptado para ser administrable antes de dicho componente terapéutico complementario .
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771525P | 2013-03-01 | 2013-03-01 | |
| US201361887165P | 2013-10-04 | 2013-10-04 | |
| PCT/US2014/019137 WO2014134355A1 (en) | 2013-03-01 | 2014-02-27 | Drug combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015011147A MX2015011147A (es) | 2016-04-28 |
| MX366967B true MX366967B (es) | 2019-07-31 |
Family
ID=50288308
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011147A MX366967B (es) | 2013-03-01 | 2014-02-27 | Combinaciones de farmacos. |
| MX2019008822A MX2019008822A (es) | 2013-03-01 | 2015-08-27 | Combinaciones de farmacos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008822A MX2019008822A (es) | 2013-03-01 | 2015-08-27 | Combinaciones de farmacos. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20160015805A1 (es) |
| EP (2) | EP3563836A1 (es) |
| JP (2) | JP6514647B2 (es) |
| KR (1) | KR20150125963A (es) |
| CN (2) | CN105025884B (es) |
| AU (1) | AU2014223348B2 (es) |
| CA (1) | CA2902433A1 (es) |
| CY (1) | CY1122554T1 (es) |
| DK (1) | DK2961388T3 (es) |
| ES (1) | ES2734023T3 (es) |
| HK (1) | HK1219663A1 (es) |
| HR (1) | HRP20191171T1 (es) |
| HU (1) | HUE044430T2 (es) |
| IL (2) | IL240894B (es) |
| LT (1) | LT2961388T (es) |
| MX (2) | MX366967B (es) |
| PH (2) | PH12015501905A1 (es) |
| PL (1) | PL2961388T3 (es) |
| PT (1) | PT2961388T (es) |
| RU (2) | RU2708246C2 (es) |
| SA (1) | SA515360959B1 (es) |
| SG (2) | SG10201707135RA (es) |
| SI (1) | SI2961388T1 (es) |
| WO (1) | WO2014134355A1 (es) |
| ZA (2) | ZA201506150B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| UA116528C2 (uk) | 2011-08-30 | 2018-04-10 | Астекс Фармасьютікалз, Інк. | Склад, набір, фармацевтична композиція, що містять похідні децитабіну, їх отримання і застосування |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| MX2016011832A (es) | 2014-03-12 | 2017-05-12 | Yeda Res & Dev | Reduccion de los niveles o la actividad de las células t reguladoras sistémicas para el tratamiento de enfermedad y lesión del sistema nervioso central (snc). |
| ME03493B (me) * | 2014-05-13 | 2020-01-20 | Medimmune Ltd | Anti-b7-h1 i anti-ctla-4 antitijela za tretman nesitnoćelijskog kancera pluća |
| EP3169326B1 (en) * | 2014-07-15 | 2021-03-31 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
| EP3205661B1 (en) | 2014-10-07 | 2021-07-07 | Cytlimic Inc. | Hsp70-derived immunity inducing peptide |
| WO2016061231A1 (en) * | 2014-10-14 | 2016-04-21 | Deciphera Pharmaceuticals, Llc | Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression |
| WO2016100851A1 (en) * | 2014-12-18 | 2016-06-23 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of retinopathy and other ocular diseases |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| US10526388B2 (en) | 2015-03-09 | 2020-01-07 | Cytlimic Inc. | Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells |
| US10842848B2 (en) | 2015-04-07 | 2020-11-24 | Cytlimic Inc. | Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein |
| WO2017004538A1 (en) * | 2015-07-02 | 2017-01-05 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
| JP6998880B2 (ja) | 2016-10-11 | 2022-02-10 | サイトリミック株式会社 | 医薬 |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| AU2018310857A1 (en) | 2017-08-03 | 2020-02-13 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
| US20210002371A1 (en) * | 2017-12-21 | 2021-01-07 | Brian A. Sherer | Combination of an anti-pd-l1 antibody and ido1 inhibitor for the treatment of cancer |
| CN108948203B (zh) * | 2018-08-09 | 2019-06-04 | 南京鼓楼医院 | 抗pd-1单克隆抗体及其制备方法和应用 |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| EP4138900A4 (en) * | 2020-04-24 | 2024-05-15 | Genexine Inc | METHODS OF TREATING CERVICAL CANCER |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| DE69943359D1 (de) | 1998-02-05 | 2011-05-26 | Glaxosmithkline Biolog Sa | Tumorassoziierte Antigenderivate der Mage-Familie, zur Herstellung von Fusionsproteinen mit T-Helper Epitope und Zusammensetzungen zur Impfung |
| DE69942037D1 (de) | 1998-12-23 | 2010-04-01 | Amgen Fremont Inc | Humane monoklonale antikörper gegen ctla-4 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| US20030148973A1 (en) | 2001-05-23 | 2003-08-07 | Peter Emtage | MAGE-A1 peptides for treating or preventing cancer |
| WO2005033278A2 (en) | 2003-09-30 | 2005-04-14 | Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus iscom |
| US20050266012A1 (en) * | 2004-05-26 | 2005-12-01 | Jean-Marie Andrieu | Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same |
| KR20070067702A (ko) | 2004-11-04 | 2007-06-28 | 화이자 프로덕츠 인크. | 유방암을 치료하기 위한 ｃｔｌａ-4 항체와 아로마타제억제제 병용 요법 |
| US20060159694A1 (en) | 2004-12-29 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in compositions for various types of cancers |
| PT2161336E (pt) | 2005-05-09 | 2013-10-03 | Ono Pharmaceutical Co | Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿ |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| IN2012DN00720A (es) * | 2009-07-06 | 2015-06-19 | Ontorii Inc | |
| SI2769737T1 (sl) * | 2009-07-20 | 2017-06-30 | Bristol-Myers Squibb Company | Kombinacija anti-ctla4 protitelesa z etoposidom za sinergistično zdravljenje proliferativnih bolezni |
| MX2012004247A (es) * | 2009-10-06 | 2012-06-25 | Angiochem Inc | Composiciones y metodos para el transporte de agentes terapeuticos. |
| GB201006096D0 (en) * | 2010-04-13 | 2010-05-26 | Alligator Bioscience Ab | Novel compositions and uses thereof |
| EP2614086A1 (en) | 2010-09-08 | 2013-07-17 | Halozyme, Inc. | Methods for assessing and identifying or evolving conditionally active therapeutic proteins |
| RU2016147206A (ru) * | 2011-04-15 | 2018-10-19 | Компуджен Лтд. | Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака |
| UA116528C2 (uk) * | 2011-08-30 | 2018-04-10 | Астекс Фармасьютікалз, Інк. | Склад, набір, фармацевтична композиція, що містять похідні децитабіну, їх отримання і застосування |
| WO2014128245A1 (en) * | 2013-02-21 | 2014-08-28 | CORAL, Sandra | Dna hypomethylating agents for cancer therapy |
-
2014
- 2014-02-27 WO PCT/US2014/019137 patent/WO2014134355A1/en active Application Filing
- 2014-02-27 US US14/771,011 patent/US20160015805A1/en not_active Abandoned
- 2014-02-27 EP EP19163282.7A patent/EP3563836A1/en not_active Withdrawn
- 2014-02-27 PT PT14710728T patent/PT2961388T/pt unknown
- 2014-02-27 PL PL14710728T patent/PL2961388T3/pl unknown
- 2014-02-27 CA CA2902433A patent/CA2902433A1/en not_active Abandoned
- 2014-02-27 DK DK14710728.8T patent/DK2961388T3/da active
- 2014-02-27 HU HUE14710728 patent/HUE044430T2/hu unknown
- 2014-02-27 KR KR1020157025503A patent/KR20150125963A/ko not_active Application Discontinuation
- 2014-02-27 SG SG10201707135RA patent/SG10201707135RA/en unknown
- 2014-02-27 RU RU2015141628A patent/RU2708246C2/ru active
- 2014-02-27 ES ES14710728T patent/ES2734023T3/es active Active
- 2014-02-27 JP JP2015560330A patent/JP6514647B2/ja not_active Expired - Fee Related
- 2014-02-27 RU RU2019138702A patent/RU2019138702A/ru unknown
- 2014-02-27 SG SG11201506727RA patent/SG11201506727RA/en unknown
- 2014-02-27 MX MX2015011147A patent/MX366967B/es active IP Right Grant
- 2014-02-27 AU AU2014223348A patent/AU2014223348B2/en not_active Ceased
- 2014-02-27 LT LTEP14710728.8T patent/LT2961388T/lt unknown
- 2014-02-27 EP EP14710728.8A patent/EP2961388B1/en active Active
- 2014-02-27 SI SI201431263T patent/SI2961388T1/sl unknown
- 2014-02-27 CN CN201480011754.5A patent/CN105025884B/zh not_active Expired - Fee Related
- 2014-02-27 CN CN201910760009.5A patent/CN110448566A/zh active Pending
-
2015
- 2015-08-24 ZA ZA201506150A patent/ZA201506150B/en unknown
- 2015-08-27 IL IL240894A patent/IL240894B/en active IP Right Grant
- 2015-08-27 MX MX2019008822A patent/MX2019008822A/es unknown
- 2015-08-28 PH PH12015501905A patent/PH12015501905A1/en unknown
- 2015-08-30 SA SA515360959A patent/SA515360959B1/ar unknown
-
2016
- 2016-07-05 HK HK16107772.1A patent/HK1219663A1/zh unknown
-
2019
- 2019-04-12 JP JP2019076111A patent/JP2019142911A/ja active Pending
- 2019-06-27 HR HRP20191171TT patent/HRP20191171T1/hr unknown
- 2019-07-10 CY CY20191100738T patent/CY1122554T1/el unknown
- 2019-07-17 US US16/514,377 patent/US20200009247A1/en not_active Abandoned
- 2019-08-16 ZA ZA2019/05426A patent/ZA201905426B/en unknown
- 2019-10-17 PH PH12019550222A patent/PH12019550222A1/en unknown
-
2020
- 2020-09-15 IL IL277385A patent/IL277385A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019550222A1 (en) | Drug combinations | |
| CY1120421T1 (el) | Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων | |
| CY1118105T1 (el) | Αγγειογενεση χρησιμοποιωντας πλακουντιακα βλαστικα κυτταρα | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| PH12018501678A1 (en) | Decitabine derivative formulation | |
| PH12016500840A1 (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| CY1119840T1 (el) | Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων | |
| MX2015012933A (es) | Micrordenamiento para suministro de agente terapeutico y metodos de uso. | |
| MX2015014408A (es) | Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico. | |
| EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
| PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| NZ711373A (en) | Fragments of p97 and uses thereof | |
| MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
| MX2022010638A (es) | Inhibidores de pde9 para el tratamiento de enfermedades perifericas. | |
| BR112015012014A2 (pt) | proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb) | |
| MX2015014046A (es) | Combinaciones de farmacos para tratar cancer. | |
| CL2015002835A1 (es) | Nuevos derivados de piridina | |
| PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
| PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| MX365392B (es) | Composición de combinación de pac-1 y doxorrubicina. | |
| MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. | |
| UA112488C2 (uk) | Три(гетеро)арилпіразоли і їх застосування | |
| AR094879A1 (es) | Formulación oral y suspensión de un fármaco oncológico | |
| TR201902863T4 (tr) | Eri̇tropoi̇eti̇n ve seftri̇akson i̇çeren farmasöti̇k bi̇r bi̇leşi̇m ve parki̇nson hastaliği demansinin tedavi̇si̇ i̇çi̇n bi̇r i̇lacin üreti̇lmesi̇nde bunun bi̇r kullanimi. | |
| MX2018003313A (es) | Celulas asesinas naturales modificadas con propiedades anti-fuctacticas y sus usos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |